A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Ranolazine (Primary)
- Indications Pulmonary hypertension; Right ventricular dysfunction
- Focus Therapeutic Use
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.
- 22 Jun 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.
- 22 Jun 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2018.